BBI-355

About Boundless Bio

Boundless Bio is a pioneer in oncology, founded to address the unmet need in cancers driven by oncogene amplification, which affect over 25% of all cancer patients. The company has established itself as the leader in the field of extrachromosomal DNA (ecDNA), leveraging its proprietary platform to develop first-in-class ecDNA-directed therapies (ecDTx). With a Phase 1 asset and a seasoned leadership team, its strategy is to validate a new therapeutic paradigm that could improve outcomes for patients with some of the most aggressive and treatment-resistant cancers.

Therapeutic Areas